--- title: "Tarsus Pharmaceuticals Balances XDEMVY Surge With Retina Bet" type: "News" locale: "en" url: "https://longbridge.com/en/news/295159256.md" description: "Tarsus Pharmaceuticals reported strong Q2 results with XDEMVY sales up 69% to $173.9 million, raising full-year guidance. The company announced a strategic acquisition of Alkeus for retinal disease treatment, involving $450 million upfront consideration and increased R&D spending. While cash reserves remain robust at $449.7 million, management acknowledged execution risks and a long timeline before ALK-001 generates revenue." datetime: "2026-08-07T00:13:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295159256.md) - [en](https://longbridge.com/en/news/295159256.md) - [zh-HK](https://longbridge.com/zh-HK/news/295159256.md) generator: "portal-rs" --- # Tarsus Pharmaceuticals Balances XDEMVY Surge With Retina Bet Tarsus Pharmaceuticals, Inc. ((TARS)) has held its Q2 earnings call. Read on for the main highlights of the call. ### Claim 55% Off TipRanks - Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions - Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks Tarsus Pharmaceuticals’ latest earnings call struck a notably upbeat tone, underscored by record XDEMVY sales and higher full‑year guidance, but tempered by the cost and long timeline of its move into retinal disease. Management emphasized strong commercial execution and financial flexibility, while acknowledging that the Alkeus acquisition will lift expenses and raise execution risks for several years. ## Record XDEMVY Sales Underscore Growth Engine Tarsus reported Q2 XDEMVY net product sales of $173.9 million, up 69% year over year and about 20% sequentially. The drug has now generated nearly $1 billion in cumulative net product sales and treated more than 700,000 patients, cementing its status as the company’s primary growth driver. ## Higher Full‑Year XDEMVY Guidance Signals Confidence On the back of this momentum, Tarsus raised its 2026 full‑year XDEMVY net product sales outlook to a range of $685 million to $705 million from $670 million to $700 million. Management framed the increase as a reflection of durable demand trends and strong execution in the eye‑care channel. ## Margins Stay Robust and Cash War Chest Deepens Gross margins held near 93%, highlighting the attractive economics of the XDEMVY franchise. The company closed the quarter with $449.7 million in cash, cash equivalents and marketable securities, giving it substantial capacity to fund clinical programs and strategic transactions. ## Commercial Momentum Builds Across Eye‑Care Practices Eye‑care professional adoption continues to accelerate, with the number of doctors prescribing XDEMVY on a near‑daily cadence doubling year over year. Retreatment rates have moved into the high teens, with management expecting a steady state around 20%, supporting recurring revenue dynamics. ## Physician Awareness and Demand Increasing More than 80% of surveyed physicians said they expect to boost XDEMVY prescribing, signaling further runway for growth. Unaided awareness of the underlying disease has climbed to about 30%, an important leading indicator for continued adoption as education efforts expand. ## Consumer Marketing Drives Direct Patient Pull‑Through Consumer‑focused campaigns are paying off, generating a 19% rise in high‑value website actions such as “Find a Doctor” and use of the AI concierge tool. Overall website engagement is up roughly 30%, and management noted more patients are now requesting XDEMVY by name in clinic visits. ## Alkeus Deal Marks Strategic Retina Expansion Tarsus announced the acquisition of Alkeus, bringing in ALK‑001 and a foothold in retinal disease, particularly Stargardt. The transaction includes $450 million in upfront consideration split between $270 million in cash and $180 million in stock, plus up to $350 million in milestones and low single‑digit tiered royalties. ## ALK‑001 Data Supports Long‑Term Retina Optionality ALK‑001, or gildeuretinol, has been tested in more than 400 patients with up to seven years of exposure, with management emphasizing favorable tolerability. The Phase III NORTHSTAR trial is enrolling roughly 230 patients aged eight to 45, building on prior data that showed about a 29% reduction in atrophic lesion growth versus placebo. ## Capital Backing from Healthcare Investors To help fund the Alkeus transaction, Tarsus secured $125 million via a private placement with healthcare‑focused investors. Management framed this financing as validation of the strategic retina pivot and a way to preserve balance‑sheet flexibility while absorbing sizable upfront costs. ## R&D Spending Set for a Meaningful Step‑Up Full‑year R&D expense guidance jumped to a range of $190 million to $210 million from $115 million to $135 million, largely due to a $75 million upfront payment tied to iRenix. This marks a material increase in near‑term operating spend as the company leans harder into pipeline development. ## Cash Outlay and Equity Issuance Raise Financial Risk The Alkeus deal’s $270 million cash component, $180 million in common stock and up to $350 million in milestones represent a significant financial commitment. While management believes its cash position is sufficient, investors will be watching for potential liquidity pressure or dilution as these obligations come due. ## Lengthy Timeline to ALK‑001 Revenue Opportunity NORTHSTAR’s primary topline results are not expected until the second half of 2029, creating a multi‑year gap before ALK‑001 could contribute meaningfully to revenue. This long horizon means XDEMVY will need to carry the growth story while retina investments remain in the value‑build phase. ## Competitive Stargardt Landscape Adds Execution Risk In Stargardt, competitor tinlarebant from Belite has a head start in Phase III development, raising competitive questions around trial enrollment and eventual market share. Tarsus believes ALK‑001 differentiates on safety and outcomes such as LLVA and atrophy measures, but investors may remain cautious. ## Seasonality Weighs on Near‑Term Revenue Cadence Management highlighted typical summer seasonality in eye care, with vacations and conferences potentially tempering near‑term growth trends. Guidance for second‑half revenue cadence was described as conservative, with expectations for stronger contributions in the fourth quarter. ## Retina Launch Model Will Add SG&A Complexity Moving into retina will require a more concentrated commercial approach focused on roughly 3,500 physicians, including about 500 performing intravitreal injections and around 2,000 prescribers. Tarsus anticipates adding 50 to 75 sales representatives, increasing SG&A and operational complexity. ## Payer and Pricing Dynamics Remain Unclear Management referenced high price benchmarks in rare retinal diseases, around $350,000 per year, and a challenging payer environment. Even with confidence in ALK‑001’s clinical value, reimbursement and access constraints could limit real‑world uptake if pricing is not carefully calibrated. ## Guidance Highlights Strong Core Business and Higher Spend Tarsus now expects 2026 XDEMVY net product sales of $685 million to $705 million, with gross margins holding near 93% and full‑year SG&A guided to $545 million to $565 million. R&D is forecast at $190 million to $210 million, excluding the pending Alkeus acquisition, and the company points to normal seasonality, retreatment rates near 20% and a path toward a potential $2 billion‑plus XDEMVY peak. Overall, the earnings call showcased a company balancing powerful near‑term cash generation with an aggressive push into retina that will take years to play out. For investors, XDEMVY’s momentum and margins are clear positives, while the Alkeus acquisition introduces higher spending, competitive uncertainty and a long wait for proof that the retina bet will pay off. ### Related Stocks - [TARS.US](https://longbridge.com/en/quote/TARS.US.md) ## Related News & Research - [Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition](https://longbridge.com/en/news/295115298.md) - [Tarsus to buy Alkeus in deal worth about $450 million upfront](https://longbridge.com/en/news/295097320.md) - [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md) - [Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half](https://longbridge.com/en/news/296638124.md) - [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**